10 Best Stocks That Will Always Grow

7. AbbVie Inc. (NYSE:ABBV)

Number of Hedge Fund Holders: 85

AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.

In a report released on April 17, Vamil Divan from Guggenheim maintained a Buy rating on AbbVie Inc. (NYSE:ABBV) and set a price target of $214.00. Analysts are optimistic about AbbVie Inc.’s (NYSE:ABBV) growth, primarily because of its two blockbuster drugs, Skyrizi and Rinvoq, two of its top three sellers in 2024. These drugs, which target dermatology, rheumatology, psoriatic diseases, and inflammatory bowel disorders, are projected to exceed $27 billion in annual sales by 2027.

AbbVie Inc. (NYSE:ABBV) is poised for growth this year since Humira’s patent expiration, with analyst seeing record sales this year and the next. Since revenue growth is bouncing back, the market anticipates a 12% annualized earnings growth in the next 3-5 years, shedding a positive light on the company’s operations and ranking it seventh on our list of the 10 best stocks that will always grow. AbbVie Inc. (NYSE:ABBV) also announced a dividend increase of 5.8%, effective February 2025, continuing its trend of increasing dividends for 12 consecutive years.